Part,  Chapter, Paragraph

 1    I,     2. 10.  1|      based on their genomic risk profile. The upcoming post-genomic
 2    I,     2. 10.  1|        on the individual genomic profile.~So far healthcare systems,
 3    I,     3.  2    |          States have a different profile. Except for Cyprus and Malta
 4   II,     5.  2.  5|  favourable effects on the lipid profile (mono-and polyunsaturated,
 5   II,     5.  2.  7|    Favorable Cardiovascular Risk Profile in Young Women and Long-term
 6   II,     5.  2.  7|       2005): Cardiovascular risk profile earlier in life and Medicare
 7   II,     5.  2.  7|    Favorable cardiovascular risk profile (Low Risk) and 10-year stroke
 8   II,     5.  2.  7|    Favorable cardiovascular risk profile and 10-year coronary heart
 9   II,     5.  4.  1|           observed that the cost profile during the natural history
10   II,     5.  4.  2| accurately recorded.~To make the profile more accurate, such information
11   II,     5.  4.  2|   diabetic subjects with a lipid profile in the last 12 months~14~
12   II,     5. 14.  8|            WHO Oral Country/Area Profile. WHO, Geneva, Switzerland.
13   II,     6.  3.  1|         the last decade saw high profile crises such as SARS and
14   II,     6.  3.  1|      consequences of recent high profile outbreaks,~ ~has given a
15   II,     6.  3.  3|         would help to define the profile of HPV strains most prevalent
16   II,     9        |   obesity). The atherogenic risk profile of older women is appreciably
17   II,     9        |    evolution of the adverse risk profile. Large randomized, placebo-controlled
18   II,     9.  1.  2|      differences in maternal age profile between countries (Dolk
19   II,     9.  2.  5|     suggesting that despite high profile support this has not had
20   II,     9.  3.  1|   obesity). The atherogenic risk profile of older women is appreciably
21   II,     9.  3.  1|    evolution of the adverse risk profile. Large randomized, placebo-controlled
22   II,     9.  5.  3|         demographic and economic profile, individuals with disabling
23  III,    10.  2.  4|      based on their genomic risk profile (Lunshof et al., 2008).~ ~
24  III,    10.  4.  2|        is used to develop a risk profile. A risk profile also includes
25  III,    10.  4.  2|   develop a risk profile. A risk profile also includes the risk question,
26  III,    10.  5.  2|      urban or rural based on the profile of the respective settlements.
27  III,    10.  5.  2|     Netherlands~ ~A rural health profile of the UK (North West UK)
28  III,    10.  6.  2|          inequalities: Europe in profile“ (Mackenbach, 2006), commissioned
29  III,    10.  6.  2|          inequalities: Europe in profile“ (Mackenbach, 2006) and
30  III,    10.  6.  2|          inequalities: Europe in profile [on-line publication available
31   IV,    11.  3.  1|          their quality assurance profile and serves legal, contractual
32   IV,    11.  5.  4|      risk based upon the donor’s profile is critical to rational
33   IV,    11.  6.  4|   adjusted depending on the risk profile of the population covered
34   IV,    11.  6.  4|        to variations in the need profile of the population.~ ~One
35   IV,    12.  2    |  favourable effects on the lipid profile (mono-and polyunsaturated,